Nanomedicines for Cutaneous Leishmaniasis

Sousa-Batista, Ariane de Jesus; Rossi-Bergmann, Bartira

doi:10.5772/intechopen.75750

Cited by 8 publications

(6 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this way, the macrophages take up the drug-loaded nanocarrier by phagocytosis, where they will directly act on the parasites. This allows the drugs to reach an effective intracellular concentration, along with a reduction in toxicity and dosage of drugs [120,121]. Furthermore, there are two types of vectoring procedure, active and passive vectoring, which could affect the distribution and uptake.…”

Section: Nanotechnology: a New Horizon For Management Of Leishmaniasismentioning

confidence: 99%

Current Strategies and Recent Advances in Nanostructured Delivery Systems for Managing Leishmaniasis-a Review

Chaurasia

Jain

2022

JASR

View full text Add to dashboard Cite

Neglected tropical diseases (NTDs) comprise of a group of 17th infectious conditions endemic in many developing countries. Among these diseases, deadly, prevalent parasitic infection such as leishmaniasis, presents a significant global burden which is responsible for high morbidity/mortality rate especially in low-and middle-income/developed countries transmitted by phlebotomines sandflies. As per the WHO report, a total of 0.7-1.0 million new leishmaniasis cases, which are spread by 23 leishmania species in more than 98 countries are estimated with an alarming 26,000-65,000 death toll every year. The disease can be characterized by at least four syndromes: cutaneous leishmaniasis (CL), muco-cutaneous leishmaniasis (MCL), visceral leishmaniasis (VL) also known as kala-azar in the Indian sub-continent or black fever, which is the most firm form of the disease being lethal if untreated and post-kala-azar dermal leishmaniasis (PKDL). The lack of cheap, portable, easy to use diagnostic tools exhibiting high efficiency and specificity impede the early diagnosis of the disease. Its intracellular nature and disseminated locations of parasite, limited number of chemotherapeutic agents, increasing incidences of resistance to first line drugs, along with the cost, toxicities, low patient compliance and require long-term regimen and usually hospitalization, pose a great challenge to formulation scientists that have necessitated effective management of leishmaniasis infection by modulating the delivery of existing drugs. Over the past decade, research on development of alternative treatments such as nanotechnology-based drug delivery systems (nanoparticles, nanotubes, nanosuspensions, liposomes, nanovaccines, etc.), use of natural products as well as development of antileishmanial vaccine has been extensively investigated due to their unique properties, such as bioavailability, lowered toxicity, targeted drug delivery, high biocomatibilty and biodegradability. To identify all relevant literature, we searched Web of Sciences, Scopus, PubMed, NCBI, Scielo, Google Scholar, and profiled studies published between 1986 and 2020. The aim of this review is to summarize new advances and new strategies used on leishmaniasis therapy addressing alternative and innovative treatment paths such as combination or multi-drug uses, immunomodulation, drug repurposing and the nanotechnology-based drug delivery systems have been used to improve the therapeutic aspects of existing antileishmanial drugs, presenting a critical review and some suggestions for improving drug delivery.

show abstract

Section: Nanotechnology: a New Horizon For Management Of Leishmaniasismentioning

confidence: 99%

Current Strategies and Recent Advances in Nanostructured Delivery Systems for Managing Leishmaniasis-a Review

Chaurasia

Jain

2022

JASR

View full text Add to dashboard Cite

show abstract

“…AmBisome is the only liposomal formulation available to treat leishmaniasis and is superior to other formulations of amphotericin B because of the significant reduction in toxicity. Many other nanoparticle formulations for both topical and systemic administration, have been tested against CL (for a comprehensive list see ref. 91 ) but none are currently in development.…”

Section: Drug Development Paradigmmentioning

confidence: 99%

Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities

Bocxlaer

Croft

2021

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

“…In this way, the macrophages take up the drug-loaded nanocarrier by phagocytosis, where they will directly act on the parasites (Figure 3). This allows the drugs to reach an effective intracellular concentration, along with a reduction in toxicity and dosage of drugs [62,63]. Furthermore, there are two types of vectoring procedure, active and passive vectoring, which could affect the distribution and uptake.…”

Section: Nanotechnology: a New Horizon For Treatment Of Leishmaniasismentioning

confidence: 99%

Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

et al. 2019

View full text Add to dashboard Cite

Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350 million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but they had toxic side effects. Various nanotechnology-based techniques and products have emerged as anti-leishmanial drugs, including liposomes, lipid nano-capsules, metal and metallic oxide nanoparticles, polymeric nanoparticles, nanotubes and nanovaccines, due to their unique properties, such as bioavailability, lowered toxicity, targeted drug delivery, and biodegradability. Many new studies have emerged with nanoparticles serving as promising therapeutic agent for anti-leishmanial disease treatment. Liposomal Amphotericin B (AmB) is one of the successful nano-based drugs with high efficacy and negligible toxicity. A new nanovaccine concept has been studied as a carrier for targeted delivery. This review discusses different nanotechnology-based techniques, materials, and their efficacies in leishmaniasis treatment and their futuristic improvements.

show abstract

Nanomedicines for Cutaneous Leishmaniasis

Cited by 8 publications

References 77 publications

Current Strategies and Recent Advances in Nanostructured Delivery Systems for Managing Leishmaniasis-a Review

Current Strategies and Recent Advances in Nanostructured Delivery Systems for Managing Leishmaniasis-a Review

Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities

Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

Contact Info

Product

Resources

About